We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+0.81%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$22.8B
AUM Growth
+$1.74M
Cap. Flow
+$81.8M
Cap. Flow %
0.36%
Top 10 Hldgs %
82.65%
Holding
132
New
12
Increased
20
Reduced
6
Closed
10

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$137M
2
PACB icon
Pacific Biosciences
PACB
+$66.5M
3
KOD icon
Kodiak Sciences
KOD
+$50.2M
4
BLUE
bluebird bio
BLUE
+$50.2M
5
TVTX icon
Travere Therapeutics
TVTX
+$34M

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$144M
2
ADCT icon
ADC Therapeutics
ADCT
+$34.5M
3
AMRN
Amarin Corp
AMRN
+$22.6M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$20.4M
5
NVTA
Invitae Corporation
NVTA
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 97.88%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OPT
51
DELISTED
Opthea Limited American Depositary Shares
OPT
$27.1M 0.12%
3,382,797
-29,265
-0.9% -$222K
BCAB icon
52
BioAtla
BCAB
$5.46M
$24.3M 0.11%
16,500
– –
KDNY
53
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$24.3M 0.11%
1,903,069
+822,676
+76% +$10.8M
NVAX icon
54
Novavax
NVAX
$1.21B
$22.5M 0.1%
108,756
-35,000
-24% -$7.71M
RETA
55
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$22.5M 0.1%
223,976
– –
BCEL
56
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$22M 0.1%
3,532,760
– –
DSGN icon
57
Design Therapeutics
DSGN
$743M
$21.1M 0.09%
1,436,636
– –
ACHL
58
DELISTED
Achilles Therapeutics
ACHL
$20.2M 0.09%
2,591,366
– –
CRNX icon
59
Crinetics Pharmaceuticals
CRNX
$8.88B
$19.4M 0.09%
920,656
– –
DICE
60
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$19.3M 0.08%
+588,235
New +$20M
CNTA
61
DELISTED
Centessa Pharmaceuticals
CNTA
$18.8M 0.08%
1,127,273
+727,273
+182% +$15.1M
AXSM icon
62
Axsome Therapeutics
AXSM
$11.8B
$17.8M 0.08%
539,057
– –
SRZN icon
63
Surrozen
SRZN
$217M
$17.7M 0.08%
+166,667
New +$23.5M
OTIC
64
DELISTED
Otonomy, Inc.
OTIC
$14.8M 0.06%
7,694,038
+471,564
+7% +$800K
CYT
65
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$14.3M 0.06%
812,640
– –
MIRM icon
66
Mirum Pharmaceuticals
MIRM
$6.58B
$12.9M 0.06%
647,313
– –
ALBO
67
DELISTED
Albireo Pharma Inc
ALBO
$12.9M 0.06%
412,466
– –
ALT icon
68
Altimmune
ALT
$580M
$12.1M 0.05%
1,072,038
– –
TCRX icon
69
TScan Therapeutics
TCRX
$48.1M
$11.9M 0.05%
+1,425,000
New +$13.2M
ANAB icon
70
AnaptysBio
ANAB
$1.53B
$11.6M 0.05%
427,179
– –
AUPH icon
71
Aurinia Pharmaceuticals
AUPH
$1.92B
$11.5M 0.05%
520,523
-599,439
-54% -$9.51M
XENE icon
72
Xenon Pharmaceuticals
XENE
$6.16B
$11.5M 0.05%
751,639
– –
TNGX icon
73
Tango Therapeutics
TNGX
$4.16B
$9.7M 0.04%
+750,000
New +$8.99M
MGNX icon
74
MacroGenics
MGNX
$235M
$9.27M 0.04%
442,579
+241,900
+121% +$5.83M
KRTX
75
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$8.56M 0.04%
69,966
– –
1 2
3
4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2021 Portfolio in Review

As of Q3 2021, Baker Bros. Advisors held 132 positions worth $22.8B, up 0.01% from $22.8B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Baker Bros. Advisors's Q3 2021 filing shows 12 new, 20 increased, 6 reduced and 10 closed positions. Its largest new stake was Surrozen: 166,667 shares worth $17.7M. The largest sale was Apellis Pharmaceuticals, an estimated $144M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q3 2021 buy was Surrozen: 166,667 shares worth $17.7M.
  • Baker Bros. Advisors added most to Ascendis Pharma A/S in Q3 2021, an estimated $137M increase.
  • Baker Bros. Advisors's biggest Q3 2021 reduction was Amarin Corp, cutting an estimated $22.6M.
  • Baker Bros. Advisors fully exited Apellis Pharmaceuticals in Q3 2021, selling an estimated $144M.
  • Baker Bros. Advisors's ten largest holdings make up 83% of its $22.8B portfolio in Q3 2021.
  • Baker Bros. Advisors opened 12 new positions and closed 10 in Q3 2021.
  • Baker Bros. Advisors's portfolio value rose 0.01% quarter-over-quarter to $22.8B.

Based on Baker Bros. Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.